Resonant Clinical Solutions Expands Advanced-Therapy and Cryogenic Storage Capabilities with Acquisition of Creapharm Bioservices

Resonant Clinical Solutions has announced the acquisition of Creapharm Bioservices, a France-based biobanking and cryogenic storage provider, for an undisclosed amount. The transaction, which was finalized on September 3, 2026, aims to enhance Resonant's Biorepository capabilities in Europe, thereby strengthening its support for complex clinical programs, particularly those involving cell and gene therapies.

Creapharm Bioservices, located in Bailly-Romainvilliers, France, specializes in biobanking and offers advanced cryogenic storage solutions for biotherapeutics and biological samples. Its services include vapor-phase nitrogen storage at temperatures as low as -196°C, mechanical freezer and cold storage options, as well as compliance with Good Manufacturing Practice (GMP) and Good Distribution Practice (GDP) standards. The acquisition comes at a time when the demand for specialized storage and handling of sensitive biological materials is increasingly critical, as clinical pipelines shift towards advanced modalities.

The strategic rationale behind this acquisition is clear. As clinical trials become more complex, particularly with the rise of advanced therapy medicinal products (ATMPs), life sciences companies require partners with specialized expertise and infrastructure. A recent study by IQVIA highlighted that non-small-molecule assets accounted for 46% of Phase I–III clinical trial starts in 2024, a significant increase from 38% five years prior. This trend underscores the growing need for robust biorepository services that can accommodate the intricacies of modern clinical trials.

By integrating Creapharm into its Biorepository business, Resonant is poised to enhance its service offerings significantly. The acquisition not only expands its geographical footprint but also bolsters its technical capabilities in cryogenic storage and the management of genetically modified organisms (GMOs). This strategic move is expected to provide Resonant's clients with improved support for managing sensitive materials and complex clinical programs, thereby advancing the company's mission to streamline the clinical trial lifecycle.

Looking ahead, the acquisition of Creapharm Bioservices positions Resonant Clinical Solutions favorably within the evolving landscape of clinical research. As the demand for specialized biorepository services continues to grow, Resonant is well-equipped to meet the needs of pharmaceutical and biotechnology companies, contract research organizations, and other stakeholders in the life sciences sector. This transaction not only reflects a strategic expansion for Resonant but also highlights the increasing importance of specialized services in supporting the future of clinical development.